While biomolecule-based therapeutics offer the potential of increased efficacy with reduced non-specific activity compared to small-molecule drugs
Written byRandall C Willis
| 1 min read
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.
UNIVERSITY PARK, Penn.—While biomolecule-based therapeutics offer the potential of increased efficacy with reduced non-specific activity compared to small-molecule drugs, their production at scales approximating that of medical chemistry remains a challenge. For many products, bioproduction in organisms like plants and animals seems to be the key, but shuffling the appropriate genes has been a challenge.
Recently, however, researchers at Penn State University (PSU) developed a way to introduce genes for therapeutic biomolecules into mushrooms that is very similar to the mechanism of gene transfer between bacteria. The researchers first introduced the gene of interest into Agrobacterium, and then co-culture mushroom cells with the bacteria, during which time, gene transfer occurs. They then kill off any unmodified mushroom cells.
"With mushrooms, we can use commercial technology to convert the vegetative tissue from mushroom strains stored in the freezer into vegetative seed," says PSU plant pathologist Dr. Charles Peter Romaine. "A crop from which drugs may be extracted could be ready in weeks."
To date, the researchers have transferred an antibiotic resistance gene, but don't expect any difficulties in transferring other biopharmaceutical genes such as insulin. PSU holds the patent for the technology, which is exclusively licensed to biotechnology company Agariger, Inc., cofounded by Romaine.
This person does not yet have a bio.View Full Profile
